Related Experiment Video

Updated: Jun 20, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[AT1-blockers in the treatment of hypertension]

J Widimský1

  • 1Centrum pro hypertenzi III. interní kliniky 1 lékarské fakulty UK a VFN Praha. jwidi@lf1.cuni.cz

Vnitrni Lekarstvi
|September 30, 2009
PubMed

Insights

Angiotensin receptor antagonists (AT1-blockers) are effective antihypertensive drugs for monotherapy or combination treatment. This review covers their mechanisms, clinical trial results, and use in managing hypertension.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Context:

  • Angiotensin receptor antagonists (AT1-blockers) represent a significant class of antihypertensive medications.
  • These drugs are widely utilized in managing high blood pressure, both as standalone treatments and in combination therapies.

Purpose:

  • To elucidate the mechanisms underlying the antihypertensive effects of AT1-blockers.
  • To review the outcomes of major clinical trials involving AT1-blockers.
  • To outline the established indications for AT1-blockers in hypertension management.

Summary:

  • AT1-blockers function by inhibiting the renin-angiotensin-aldosterone system, leading to vasodilation and reduced blood pressure.
  • Large-scale clinical studies have consistently demonstrated the efficacy and safety of AT1-blockers in diverse patient populations.
  • Their established role in hypertension underscores their importance in cardiovascular disease prevention and treatment.

Impact:

  • Provides a comprehensive overview of AT1-blockers for clinicians and researchers.
  • Highlights the therapeutic significance of AT1-blockers in contemporary hypertension guidelines.
  • Contributes to the understanding of effective blood pressure control strategies.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...